Latest News

Bison Capital Acquisition Corp. and Xynomic Pharmaceuticals, Inc. Announce Signing of Definitive Merger Agreement
Image 09/29/2018 Uncategorized admin

NEW YORK, NY and SHANGHAI, China, Sept. 12, 2018 (GLOBE NEWSWIRE) –– Bison Capital Acquisition Corp. (“BCAC”, NASDAQ: BCAC) and Xynomic Pharmaceuticals, Inc. (“Xynomic”), a U.S.-China clinical stage innovative oncology drug development company, today jointly announced that they have signed a definitive merger agreement. Upon completion of the merger, Xynomic will become a wholly-owned subsidiary

Xynomic Privacy Shield Data Privacy Statement
Image 09/10/2018 Uncategorized admin

Privacy Shied Compliant Privacy Policy Xynomic Pharmaceuticals, Inc. (“Xynomic”) participates in the Privacy Shield, detailed information of which can be found at  Xynomic adheres to each of the Privacy Shield Principles and is committed to subjecting to the Principles all personal information received from the EU in reliance on the EU-U.S. Privacy Shield Framework.

Mark Xu ( Chairman and CEO of Xynomic ) Invited to Participate in JP Morgan Healthcare Conference
01/04/2018 Uncategorized admin

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

Xynomic Pharma Initiates Ph 1/2 Trial Combining Abexinostat with Ibrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and Mantle Cell Lymphoma (r/r MCL)
12/03/2017 Uncategorized admin

CHEYENNE, Wyo., Dec. 1, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it will initiate a Ph 1/2 trial, in collaboration with Janssen R&D, LLC (Janssen Pharmaceutical Companies of Johnson & Johnson, hereafter Janssen) and Memorial Sloan Kettering Cancer Center (MSK), to combine Abexinostat with Ibrutinib against r/r DLBCL

Xynomic Pharma Acquires Global Rights of Boehringer Ingelheim’s BI 882370, a Novel and Potent RAF Inhibitor against Solid Tumors
11/07/2017 Uncategorized admin

CHEYENNE, Wyo., Oct. 30, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it has acquired exclusive global rights to develop, manufacture and commercialize BI 882370, a 2nd-generation RAF inhibitor, from Boehringer Ingelheim, a top-20 global pharmaceutical company.  Under the terms of the agreement Xynomic will pay upfront, milestone and

Xynonic Invited to Present at the Prestigious Berstein China Oncology Day in Hong Kong on June 21
05/29/2017 Uncategorized admin

Mr. Y. Mark Xu, Chairman, CEO and President, has been invited to speak at this high profile conference. Other presenting companies include Roche, Sanofi, Hengrui and Sino Biopharm. The venue is Mandarin Oriental Hotel, Hong Kong. This conference is expected to draw attendance of over 100 leading Asian institutional investors and high net worth individuals.

Xynomic Pharma and UCSF Entered Strategic Partnership in Conducting a Phase 2/3 Trial of Abexinostat against Renal Cell Carcinoma
05/26/2017 Uncategorized admin

CHEYENNE, Wyo., May 22, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug R&D company, today announced that it has entered into a strategic partnership with the University of California San Francisco (“UCSF”) to conduct PAX Study, a multi-national, multi-center, randomized Phase 2/3 study of Pazopanib plus Abexinostat versus Pazopanib monotherapy in patients with locally

Abexinostat Significantly Reversed Treatment Resistance in GSK’s Pazopanib- and other VEGF inhibitor-refractory Tumors in a 51-Patients Ph 1b Trail Led by Professor Munster at UCSF
03/17/2017 Uncategorized admin

Sponsored by NCI and UCSF 51 patients (72% had received two or more lines of therapy in the locally advanced or metastatic setting), Phase 1b, open-label, dose-escalation/expansion trial of Abexinostat in combination with GSK’s pazopanib Abexinostat well tolerated in combination with pazopanib First ever clinical trial to test the hypothesis that epigenetic modification with HDAC

Xynomic Pharma has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications
03/11/2017 Uncategorized admin

March. 8, 2017 — Xynomic Pharmaceuticals, Inc., a US-China oncology startup, has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications from Resarci Therapeutics of West Lafayette, Indiana. It will be tested as a treatment for prostate, pancreatic and other solid tumors. Xynomic will pay $1.2 million in upfront and milestone payments,

Xynomic Pharma Has Acquired Worldwide Rights of Abexinostat
02/25/2017 Uncategorized admin

CHEYENNE, Wyoming, Feb. 24, 2017 /PRNewswire/ — Xynomic Pharmaceuticals, Inc., an oncology drug research and development company, today announced that it has acquired exclusive worldwide rights to develop, manufacture and commercialize Abexinostat, a potentially best-in-class innovative HDAC inhibitor targeting hematological and solid tumors. To date a total of 17 Phase 1 and 2 clinical trials